Image For Activity Cover
Rhythm Theater - Neuromodulation for Heart Failure, a New Therapeutic Frontier. BAROSTIM NEO the World’s First Neuromodulation Therapy for Heart Failure: Clinical Evidence, Patient Selection and Implant Practices
The esteemed group of electrophysiologists and heart failure specialists review autonomic modulation therapies for the treatment of heart failure. The group introduces the BAROSTIM NEO device, the world’s first FDA approved neuromodulation device for the treatment of heart failure. The team discusses BAROSTIM NEO clinical evidence, patient selection, implantation procedure, and the clinical and technological plans for the next generation of BAROSTIM NEO. 
Thomas F. Deering, MBA, MD, FHRS, CCDS
Bradley Knight, MD, FHRS
Larry Chinitz, MD, FHRS
Michael R. Gold, MD, PhD, FHRS
Luanda Grazette, MD
Marwan Bahu, MD, FHRS
Khaled Awad, MD
For More Information
For more information on BAROSTIM NEO please contact the CVRx team at
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
  Heart Rhythm Society
1325 G Street NW, Suite 400
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
© Heart Rhythm Society
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
Android App Download IOS App Download Powered By